Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma

Bone Marrow Transplant. 2020 Sep;55(9):1865-1867. doi: 10.1038/s41409-020-0844-2. Epub 2020 Feb 26.

Authors

Katia Mancuso¹, Paola Tacchetti¹, Lucia Pantani¹, Serena Rocchi¹, Ilaria Rizzello¹, Isola Caratozzolo¹, Gabriella De Cicco¹, Alessio Fusco¹, Nicoletta Testoni¹, Carolina Terragna¹, Giulia Marzocchi¹, Marina Martello¹, Enrica Borsi¹, Luca Dozza¹, Michele Cavo², Elena Zamagni¹

Affiliations

¹ Seràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, S. Orsola Malpighi Hospital, Bologna, Italy.
² Seràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, S. Orsola Malpighi Hospital, Bologna, Italy. michele.cavo@unibo.it.

PMID: 32103147
DOI: 10.1038/s41409-020-0844-2

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bortezomib / therapeutic use
Dexamethasone / therapeutic use
Humans
Lenalidomide / therapeutic use
Multiple Myeloma* / drug therapy
Transplantation, Autologous
Treatment Outcome

Substances

Bortezomib
Dexamethasone
Lenalidomide